Compare Stocks → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ANVSNASDAQ:EVOKNASDAQ:ITRMNASDAQ:JAGXNASDAQ:MBRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$10.06+2.1%$10.36$5.42▼$22.49$110.76M1.59265,139 shs224,288 shsEVOKEvoke Pharma$0.48$0.62$0.42▼$2.42$4.05M0.2256,073 shs1,943 shsITRMIterum Therapeutics$1.43$1.51$0.62▼$2.50$23.50M2.36523,775 shs59,817 shsJAGXJaguar Health$0.16-11.3%$0.09$0.05▼$1.22$43.34M1.3550.67 million shs31.20 million shsMBRXMoleculin Biotech$4.65+2.9%$7.07$4.28▼$15.75$10.37M1.9530,571 shs10,562 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+8.93%-19.02%+9.78%-15.48%-33.24%EVOKEvoke Pharma-12.79%-11.35%-21.38%-37.82%-77.20%ITRMIterum Therapeutics-0.69%-11.73%-13.33%-24.74%+20.17%JAGXJaguar Health+7.40%+64.74%+157.04%+74.83%-72.32%MBRXMoleculin Biotech+6.07%-5.02%-42.22%-44.66%-62.17%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio1.6543 of 5 stars3.41.00.00.03.11.70.6EVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics0.8541 of 5 stars3.52.00.00.00.60.00.6JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AMBRXMoleculin Biotech2.2833 of 5 stars3.53.00.00.02.90.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio2.75Moderate Buy$27.75175.84% UpsideEVOKEvoke PharmaN/AN/AN/AN/AITRMIterum Therapeutics3.00Buy$6.00319.58% UpsideJAGXJaguar HealthN/AN/AN/AN/AMBRXMoleculin Biotech3.00Buy$35.00652.69% UpsideCurrent Analyst RatingsLatest ITRM, EVOK, MBRX, JAGX, and ANVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/2/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.004/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/21/2024ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/28/2024ANVSAnnovis BioBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$9.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AEVOKEvoke Pharma$5.18M0.78N/AN/A($0.77) per share-0.62ITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AJAGXJaguar Health$9.76M4.44N/AN/A$0.07 per share2.24MBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$6.22N/AN/AN/AN/A-446.06%-257.97%5/9/2024 (Estimated)EVOKEvoke Pharma-$7.79M-$2.33N/A∞N/A-150.43%-517.99%-91.83%5/20/2024 (Estimated)ITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)JAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)MBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)Latest ITRM, EVOK, MBRX, JAGX, and ANVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023EVOKEvoke PharmaN/A-$0.59-$0.59-$0.59N/A$1.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.392.39EVOKEvoke PharmaN/A2.252.09ITRMIterum Therapeutics3.631.891.89JAGXJaguar Health6.332.001.34MBRXMoleculin BiotechN/A3.863.86OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%EVOKEvoke PharmaN/AITRMIterum Therapeutics9.21%JAGXJaguar Health12.04%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio38.30%EVOKEvoke Pharma11.78%ITRMIterum Therapeutics5.40%JAGXJaguar Health0.16%MBRXMoleculin Biotech6.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio511.01 million6.79 millionOptionableEVOKEvoke Pharma48.48 million7.48 millionNot OptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableJAGXJaguar Health49276.22 million275.77 millionNo DataMBRXMoleculin Biotech182.23 million2.08 millionNot OptionableITRM, EVOK, MBRX, JAGX, and ANVS HeadlinesSourceHeadlineMoleculin Biotech Says EMA Grants Orphan Drug Designation To Annamycin To Treat AMLmarkets.businessinsider.com - April 18 at 9:42 AMEuropean Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)prnewswire.com - April 18 at 8:30 AMRoth Mkm Reiterates Buy Rating for Moleculin Biotech (NASDAQ:MBRX)americanbankingnews.com - April 14 at 1:58 AMMoleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.comamericanbankingnews.com - April 13 at 2:22 AMMoleculin Biotech Inc (MBRX)investing.com - April 12 at 12:07 AMMoleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic Effectsmarkets.businessinsider.com - April 10 at 12:17 PMMoleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Propertiesprnewswire.com - April 10 at 8:30 AMMoleculin to Present at the MedInvest Biotech & Pharma Investor Conferencefinance.yahoo.com - March 28 at 11:23 AMMoleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLfinance.yahoo.com - March 27 at 1:35 PMMoleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunityprnewswire.com - March 27 at 9:25 AMMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 26 at 9:48 AMNews - Moleculin Biotechthepharmaletter.com - March 25 at 11:47 PMMoleculin Biotech, Inc.: Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinanznachrichten.de - March 25 at 6:45 PMMoleculin skyrockets on interim data for annamycin MB-106 trialthepharmaletter.com - March 25 at 6:45 PMMoleculin Biotech Reports Positive Interim Data From MB-106 Phase 1B/2 Study In AMLmarkets.businessinsider.com - March 25 at 9:05 AMMoleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trialfinance.yahoo.com - March 25 at 9:05 AMMoleculin Biotech, Inc.: Moleculin Reports Full Year 2023 Financial Resultsfinanznachrichten.de - March 23 at 10:20 AMMBRX Stock Earnings: Moleculin Biotech Reported Results for Q4 2023investorplace.com - March 22 at 10:03 PMMoleculin Biotech Inc Reports Fiscal Year 2023 Financial Resultsfinance.yahoo.com - March 22 at 7:18 PMMoleculin Reports Full Year 2023 Financial Resultsprnewswire.com - March 22 at 4:05 PMMoleculin Biotech announces 1-for-15 reverse stock splitinvesting.com - March 21 at 11:00 PMA Preview Of Moleculin Biotech's Earningsbenzinga.com - March 21 at 5:59 PMMoleculin Biotech, Inc.: Moleculin Announces Reverse Stock Splitfinanznachrichten.de - March 20 at 1:07 PMMoleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcastprnewswire.com - March 20 at 7:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnnovis BioNYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Evoke PharmaNASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Moleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.